Dominari (NASDAQ:DOMH) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Dominari (NASDAQ:DOMH) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings downgraded Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Dominari Price Performance

NASDAQ:DOMH opened at $2.82 on Friday. Dominari has a 1 year low of $2.68 and a 1 year high of $8.40. The stock’s 50 day simple moving average is $3.09 and its two-hundred day simple moving average is $4.19. The company has a market cap of $63.76 million, a price-to-earnings ratio of -0.73 and a beta of 0.80.

Hedge Funds Weigh In On Dominari

Large investors have recently modified their holdings of the stock. NewEdge Advisors LLC bought a new position in shares of Dominari during the 4th quarter valued at approximately $50,000. PFG Investments LLC bought a new position in shares of Dominari during the 4th quarter valued at approximately $53,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Dominari in the 4th quarter worth $96,000. Oxford Asset Management LLP purchased a new stake in shares of Dominari in the 4th quarter worth $120,000. Finally, Jane Street Group LLC purchased a new stake in shares of Dominari in the 2nd quarter worth $158,000. Institutional investors own 42.48% of the company’s stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.